These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Predominance of triple wild-type and IGF2R mutations in mucosal melanomas. Iida Y; Salomon MP; Hata K; Tran K; Ohe S; Griffiths CF; Hsu SC; Nelson N; Hoon DSB BMC Cancer; 2018 Oct; 18(1):1054. PubMed ID: 30373548 [TBL] [Abstract][Full Text] [Related]
8. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations. Williams EA; Montesion M; Shah N; Sharaf R; Pavlick DC; Sokol ES; Alexander B; Venstrom J; Elvin JA; Ross JS; Williams KJ; Tse JY; Mochel MC Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240 [TBL] [Abstract][Full Text] [Related]
10. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases. Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561 [TBL] [Abstract][Full Text] [Related]
11. Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing. Lokhandwala PM; Tseng LH; Rodriguez E; Zheng G; Pallavajjalla A; Gocke CD; Eshleman JR; Lin MT BMC Cancer; 2019 Jul; 19(1):665. PubMed ID: 31277584 [TBL] [Abstract][Full Text] [Related]
13. Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract. Cai YJ; Ke LF; Zhang WW; Lu JP; Chen YP BMC Cancer; 2021 Jun; 21(1):677. PubMed ID: 34102999 [TBL] [Abstract][Full Text] [Related]
14. Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer. Redig AJ; Capelletti M; Dahlberg SE; Sholl LM; Mach S; Fontes C; Shi Y; Chalasani P; Jänne PA Clin Cancer Res; 2016 Jul; 22(13):3148-56. PubMed ID: 26861459 [TBL] [Abstract][Full Text] [Related]
15. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands. van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725 [TBL] [Abstract][Full Text] [Related]
16. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation]. Lázár V Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354 [TBL] [Abstract][Full Text] [Related]
17. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Mar VJ; Wong SQ; Li J; Scolyer RA; McLean C; Papenfuss AT; Tothill RW; Kakavand H; Mann GJ; Thompson JF; Behren A; Cebon JS; Wolfe R; Kelly JW; Dobrovic A; McArthur GA Clin Cancer Res; 2013 Sep; 19(17):4589-98. PubMed ID: 23833303 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma. Yaman B; Akalin T; Kandiloğlu G Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015 [TBL] [Abstract][Full Text] [Related]
20. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Nissan MH; Pratilas CA; Jones AM; Ramirez R; Won H; Liu C; Tiwari S; Kong L; Hanrahan AJ; Yao Z; Merghoub T; Ribas A; Chapman PB; Yaeger R; Taylor BS; Schultz N; Berger MF; Rosen N; Solit DB Cancer Res; 2014 Apr; 74(8):2340-50. PubMed ID: 24576830 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]